FDA Approves Generic Drug but Downplays Autism Treatment Claims

The Food and Drug Administration (FDA) approved a generic formulation of the drug leucovorin on Tuesday, targeting a rare genetic condition affecting the delivery of folate to the brain. However, the agency clarified that the medication does not provide significant benefits for individuals with autism, contradicting earlier statements from political leaders, including President Donald Trump.

Leucovorin is intended for those with a genetic disorder that impacts fewer than 1 in a million people in the United States, a stark contrast to the broader autism community. The FDA’s announcement marks a notable shift from a White House press conference in September, where both Trump and Marty Makary, the FDA commissioner, suggested the drug could potentially help many children with autism, even estimating that it might benefit “20, 40, 50%” of affected children.

At the time, the conference was part of a larger initiative led by Health Secretary Robert F. Kennedy Jr. aimed at investigating the causes of autism by September. Yet, FDA officials revealed that their review focused solely on the strongest evidence, leading to the conclusion that leucovorin’s use is limited to patients with specific mutations affecting folate metabolism.

Clarifications on Leucovorin’s Efficacy

Officials indicated that one of the studies previously supporting leucovorin’s application for autism treatment was retracted earlier this year. While leucovorin is primarily recognized for its role in reducing chemotherapy side effects and treating a rare blood disorder, its effectiveness for autism remains unclear. The American Academy of Pediatrics has stated that there is insufficient evidence to recommend the routine use of leucovorin for autistic children, even those diagnosed with cerebral folate deficiency.

Some research has suggested potential benefits for a small subset of patients, but these studies have been limited in scope. The FDA’s decision comes amidst reports of increased prescriptions for leucovorin among children aged 5 to 17, which surged by 71% in the months following Trump’s September announcement. Families seeking prescriptions have encountered challenges in accessing the medication, prompting FDA officials to permit the importation of leucovorin from foreign manufacturers to alleviate supply issues. Notably, the original manufacturer, GSK, has no plans to reintroduce its version of the drug.

The initial push for a review of leucovorin stemmed from discussions between officials and an Arizona-based neurologist who has advocated for its use in autism treatment. The rationale behind the drug’s application is that certain individuals with autism possess antibodies that inhibit folate transport to the brain. However, organizations such as the Autism Science Foundation point out that many non-autistic family members of affected individuals also have these antibodies, suggesting they might not play a significant role in the condition.

While the scientific community acknowledges that multiple factors contribute to autism, there is a consensus that genetic and environmental components are key. As the FDA continues to clarify the intended use of leucovorin, many families and healthcare providers remain in search of effective treatments for autism.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.